Inhibition of myostatin in adult mice increases skeletal muscle mass and strength
Lisa-Anne Whittemore,Kening Song,Xiangping Li,Jane Aghajanian,Monique Davies,Stefan Girgenrath,Jennifer J. Hill,Mary Jalenak,Pamela Kelley,Andrea Knight,Rich Maylor,Denise O’Hara,Adele Pearson,Amira Quazi,Stephanie Ryerson,Xiang-Yang Tan,Kathleen N. Tomkinson,Geertruida M. Veldman,Angela Widom,Jill F. Wright,Steve Wudyka,Liz Zhao,Neil M. Wolfman
DOI: https://doi.org/10.1016/s0006-291x(02)02953-4
IF: 3.1
2003-01-01
Biochemical and Biophysical Research Communications
Abstract:A human therapeutic that specifically modulates skeletal muscle growth would potentially provide a benefit for a variety of conditions including sarcopenia, cachexia, and muscular dystrophy. Myostatin, a member of the TGF-beta family of growth factors, is a known negative regulator of muscle mass, as mice lacking the myostatin gene have increased muscle mass. Thus, an inhibitor of myostatin may be useful therapeutically as an anabolic agent for muscle. However, since myostatin is expressed in both developing and adult muscles, it is not clear whether it regulates muscle mass during development or in adults. In order to test the hypothesis that myostatin regulates muscle mass in adults, we generated an inhibitory antibody to myostatin and administered it to adult mice. Here we show that mice treated pharmacologically with an antibody to myostatin have increased skeletal muscle mass and increased grip strength. These data show for the first time that myostatin acts postnatally as a negative regulator of skeletal muscle growth and suggest that myostatin inhibitors could provide a therapeutic benefit in diseases for which muscle mass is limiting.
biochemistry & molecular biology,biophysics